- |||||||||| Izervay (avacincaptad pegol intravitreal solution) / Astellas
Phase classification: A Study to Establish the Safety and Tolerability of Zimura (clinicaltrials.gov) - Jan 23, 2017 P2a, N=4, Completed, Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Jan 2017 Phase classification: P2 --> P2a
- |||||||||| Fumena (vorolanib) / Tyrogenex
Enrollment closed, Monotherapy, Head-to-Head: X-82 to Treat Age-related Macular Degeneration (clinicaltrials.gov) - Jan 13, 2017 P2, N=132, Active, not recruiting, Terminated --> Suspended | Trial primary completion date: May 2016 --> Feb 2016 Recruiting --> Active, not recruiting
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: Macular EpiRetinal Brachytherapy Versus Lucentis (clinicaltrials.gov) - Dec 22, 2016 P4, N=363, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Fovista (pegpleranib) / Roche, Astellas
Trial termination, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Dec 21, 2016 P3, N=619, Terminated, Active, not recruiting --> Completed Active, not recruiting --> Terminated
- |||||||||| Fovista (pegpleranib) / Roche, Astellas
Trial termination, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Dec 21, 2016 P3, N=627, Terminated, Active, not recruiting --> Terminated Active, not recruiting --> Terminated
- |||||||||| Fovista (pegpleranib) / Roche, Astellas
Trial termination, Combination therapy: Phase 2A Open Label Safety Study of Fovista (clinicaltrials.gov) - Dec 21, 2016 P2a, N=101, Terminated, Active, not recruiting --> Terminated Active, not recruiting --> Terminated
- |||||||||| Fovista (pegpleranib) / Roche, Astellas
Phase classification, Trial termination, Combination therapy: A 24 Month Phase 2a Open Label, Randomized Study of Avastin (clinicaltrials.gov) - Dec 21, 2016 P2a, N=64, Terminated, Active, not recruiting --> Terminated Phase classification: P2 --> P2a | Active, not recruiting --> Terminated
- |||||||||| Fovista (pegpleranib) / Roche, Astellas
Trial primary completion date, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Dec 14, 2016 P3, N=627, Active, not recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> Dec 2016
- |||||||||| Fovista (pegpleranib) / Roche, Astellas
Enrollment closed, Trial primary completion date, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - Dec 14, 2016 P3, N=619, Active, not recruiting, Trial primary completion date: Jul 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2016
- |||||||||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial initiation date: Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen (clinicaltrials.gov) - Nov 27, 2016 P4, N=40, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Oct 2014
- |||||||||| Fumena (vorolanib) / Tyrogenex
Trial primary completion date, Monotherapy, Head-to-Head: X-82 to Treat Age-related Macular Degeneration (clinicaltrials.gov) - Nov 16, 2016 P2, N=132, Recruiting, Recruiting --> Active, not recruiting | Initiation date: Jun 2014 --> Oct 2014 Trial primary completion date: Oct 2016 --> Jan 2017
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Enrollment change, Trial primary completion date: PROTECT: Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - Oct 19, 2016 P1/2, N=4, Active, not recruiting, Trial primary completion date: Apr 2018 --> Mar 2019 Recruiting --> Active, not recruiting | N=88 --> 4 | Trial primary completion date: Nov 2017 --> Jul 2017
- |||||||||| hI-con1 (ICON-1) / Endpoint Health
Trial completion: EMERGE: Study Evaluating Intravitreal hI-con1 (clinicaltrials.gov) - Oct 12, 2016 P2, N=88, Completed, Initiation date: Apr 2016 --> Nov 2016 Active, not recruiting --> Completed
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Noctura400 Treatment for Diabetic Retinopathy (CANDLE) (clinicaltrials.gov) - Oct 11, 2016 P=N/A, N=240, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
|